WP
MRSN

Woodline Partners’s Mersana Therapeutics MRSN Stock Holding History

Woodline Partners’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17,424
Closed -$150K – 1013
2025
Q1 		$150K Hold
17,424
– – ﹤0.01% 883
2024
Q4 		$623K Buy
17,424
+82
+0.5% +$4.24K ﹤0.01% 813
2024
Q3 		$819K Sell
17,342
-41,350
-70% -$1.82M 0.01% 518
2024
Q2 		$2.95M Sell
58,692
-58,693
-50% -$4.24M 0.03% 386
2024
Q1 		$13.1M Buy
+117,385
New +$11.7M 0.12% 229
2023
Q4 		– Sell
-52,080
Closed -$1.65M – 594
2023
Q3 		$1.65M Buy
+52,080
New +$2.48M 0.02% 414
2023
Q1 		– Sell
-20,936
Closed -$3.07M – 726
2022
Q4 		$3.07M Buy
+20,936
New +$3.54M 0.04% 396
2022
Q3 		– Sell
-126,463
Closed -$14.6M – 798
2022
Q2 		$14.6M Buy
+126,463
New +$11.9M 0.23% 142
2020
Q3 		– Sell
-10,686
Closed -$6.25M – 202
2020
Q2 		$6.25M Buy
+10,686
New +$3.65M 0.25% 96

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Woodline Partners's MRSN Position: Q2 2025 in Review

Woodline Partners sold out of Mersana Therapeutics (MRSN) in Q2 2025, closing a stake of 17,424 shares — an estimated $150K sold.

Woodline Partners first reported a position in MRSN in Q2 2020 and held it in 9 quarters. The position peaked at $14.6M in Q2 2022. 83 funds tracked by Wall St. Rank hold MRSN as of Q2 2025.

  • Woodline Partners reported no remaining Mersana Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Woodline Partners sold 17,424 Mersana Therapeutics shares in Q2 2025, an estimated $150K.
  • Woodline Partners first reported a position in Mersana Therapeutics in Q2 2020 and held it in 9 quarters.
  • Woodline Partners's Mersana Therapeutics position peaked at $14.6M in Q2 2022.
  • 83 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2025.

Based on Woodline Partners's 13F filing for Q2 2025, filed 14 Aug 2025.